Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Cidara Therapeutics ( (CDTX) ) has issued an update.
On June 24, 2025, Cidara Therapeutics announced an agreement with several underwriters to sell approximately 7.95 million shares of its common stock at $44.00 per share in a public offering, aiming to raise around $350 million. The offering, scheduled to close on June 26, 2025, marks a significant financial move for Cidara, potentially enhancing its market position and providing capital to advance its therapeutic developments.
The most recent analyst rating on (CDTX) stock is a Buy with a $45.00 price target. To see the full list of analyst forecasts on Cidara Therapeutics stock, see the CDTX Stock Forecast page.
Spark’s Take on CDTX Stock
According to Spark, TipRanks’ AI Analyst, CDTX is a Neutral.
Cidara Therapeutics’ stock score is primarily hindered by its financial performance, marked by substantial losses and reliance on external financing. However, strong technical indicators and positive corporate events provide some optimism for future growth. The earnings call and valuation concerns, such as a negative P/E ratio, further temper the overall score.
To see Spark’s full report on CDTX stock, click here.
More about Cidara Therapeutics
Cidara Therapeutics is a biotechnology company based in San Diego, California, utilizing its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeutics. The company’s lead DFC candidate, CD388, is designed for universal prevention of influenza, and it has also developed DFCs for oncology.
Average Trading Volume: 328,106
Technical Sentiment Signal: Buy
Current Market Cap: $607.5M
For an in-depth examination of CDTX stock, go to TipRanks’ Overview page.